UA118833C2 - Одиничний варіабельний домен імуноглобуліну, який зв'язується з tnfr1 - Google Patents

Одиничний варіабельний домен імуноглобуліну, який зв'язується з tnfr1 Download PDF

Info

Publication number
UA118833C2
UA118833C2 UAA201401344A UAA201401344A UA118833C2 UA 118833 C2 UA118833 C2 UA 118833C2 UA A201401344 A UAA201401344 A UA A201401344A UA A201401344 A UAA201401344 A UA A201401344A UA 118833 C2 UA118833 C2 UA 118833C2
Authority
UA
Ukraine
Prior art keywords
binding
terminal
amino acid
beg
rgo
Prior art date
Application number
UAA201401344A
Other languages
English (en)
Ukrainian (uk)
Inventor
Клер Ешмен
Мері Берчлер
Вілдт Рудолф М Т де
Клер Холланд
Елан Пітер Люіс
Пітер Морлі
Томас Сендел
Майкл Стюард
Original Assignee
Ґлаксо Ґруп Лімітед
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Priority claimed from GBGB1121233.9A external-priority patent/GB201121233D0/en
Priority claimed from GBGB1121236.2A external-priority patent/GB201121236D0/en
Priority claimed from GBGB1121226.3A external-priority patent/GB201121226D0/en
Priority claimed from PCT/EP2012/064632 external-priority patent/WO2013014208A2/en
Application filed by Ґлаксо Ґруп Лімітед filed Critical Ґлаксо Ґруп Лімітед
Publication of UA118833C2 publication Critical patent/UA118833C2/uk

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies
    • C07K16/42—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against immunoglobulins
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
    • A61P1/04—Drugs for disorders of the alimentary tract or the digestive system for ulcers, gastritis or reflux esophagitis, e.g. antacids, inhibitors of acid secretion, mucosal protectants
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P11/00—Drugs for disorders of the respiratory system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P11/00—Drugs for disorders of the respiratory system
    • A61P11/02—Nasal agents, e.g. decongestants
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P11/00—Drugs for disorders of the respiratory system
    • A61P11/06—Antiasthmatics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P17/00—Drugs for dermatological disorders
    • A61P17/06—Antipsoriatics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P19/00—Drugs for skeletal disorders
    • A61P19/02—Drugs for skeletal disorders for joint disorders, e.g. arthritis, arthrosis
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P29/00—Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/04—Antibacterial agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/04—Antibacterial agents
    • A61P31/06—Antibacterial agents for tuberculosis
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/10—Antimycotics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/12—Antivirals
    • A61P31/14—Antivirals for RNA viruses
    • A61P31/16—Antivirals for RNA viruses for influenza or rhinoviruses
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P33/00—Antiparasitic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • A61P37/02—Immunomodulators
    • A61P37/06—Immunosuppressants, e.g. drugs for graft rejection
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • A61P37/08—Antiallergic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A61P9/10—Drugs for disorders of the cardiovascular system for treating ischaemic or atherosclerotic diseases, e.g. antianginal drugs, coronary vasodilators, drugs for myocardial infarction, retinopathy, cerebrovascula insufficiency, renal arteriosclerosis
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A61P9/12—Antihypertensives
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies
    • C07K16/18—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans
    • C07K16/22—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans against growth factors ; against growth regulators
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies
    • C07K16/18—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans
    • C07K16/28—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants
    • C07K16/2878—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants against the NGF-receptor/TNF-receptor superfamily, e.g. CD27, CD30, CD40, CD95
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/505—Medicinal preparations containing antigens or antibodies comprising antibodies
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/40—Immunoglobulins specific features characterized by post-translational modification
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/50—Immunoglobulins specific features characterized by immunoglobulin fragments
    • C07K2317/56—Immunoglobulins specific features characterized by immunoglobulin fragments variable (Fv) region, i.e. VH and/or VL
    • C07K2317/567—Framework region [FR]
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/50—Immunoglobulins specific features characterized by immunoglobulin fragments
    • C07K2317/56—Immunoglobulins specific features characterized by immunoglobulin fragments variable (Fv) region, i.e. VH and/or VL
    • C07K2317/569—Single domain, e.g. dAb, sdAb, VHH, VNAR or nanobody®
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/60—Immunoglobulins specific features characterized by non-natural combinations of immunoglobulin fragments
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/60—Immunoglobulins specific features characterized by non-natural combinations of immunoglobulin fragments
    • C07K2317/64—Immunoglobulins specific features characterized by non-natural combinations of immunoglobulin fragments comprising a combination of variable region and constant region components
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2319/00—Fusion polypeptide

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • General Health & Medical Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Immunology (AREA)
  • Veterinary Medicine (AREA)
  • Animal Behavior & Ethology (AREA)
  • Pharmacology & Pharmacy (AREA)
  • General Chemical & Material Sciences (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Public Health (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Molecular Biology (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Genetics & Genomics (AREA)
  • Biophysics (AREA)
  • Biochemistry (AREA)
  • Pulmonology (AREA)
  • Communicable Diseases (AREA)
  • Oncology (AREA)
  • Heart & Thoracic Surgery (AREA)
  • Cardiology (AREA)
  • Virology (AREA)
  • Dermatology (AREA)
  • Rheumatology (AREA)
  • Physical Education & Sports Medicine (AREA)
  • Vascular Medicine (AREA)
  • Biomedical Technology (AREA)
  • Neurology (AREA)
  • Neurosurgery (AREA)
  • Orthopedic Medicine & Surgery (AREA)
  • Tropical Medicine & Parasitology (AREA)
  • Pain & Pain Management (AREA)
  • Transplantation (AREA)
  • Otolaryngology (AREA)
  • Urology & Nephrology (AREA)
UAA201401344A 2011-08-17 2012-08-13 Одиничний варіабельний домен імуноглобуліну, який зв'язується з tnfr1 UA118833C2 (uk)

Applications Claiming Priority (6)

Application Number Priority Date Filing Date Title
US201161524488P 2011-08-17 2011-08-17
GBGB1121233.9A GB201121233D0 (en) 2011-12-12 2011-12-12 Modified proteins and peptides
GBGB1121236.2A GB201121236D0 (en) 2011-12-12 2011-12-12 Proteins and peptides
GBGB1121226.3A GB201121226D0 (en) 2011-12-12 2011-12-12 Modified proteins and peptides
PCT/EP2012/064632 WO2013014208A2 (en) 2011-07-27 2012-07-25 Antigen binding constructs
PCT/EP2012/065782 WO2013024059A2 (en) 2011-08-17 2012-08-13 Modified proteins and peptides

Publications (1)

Publication Number Publication Date
UA118833C2 true UA118833C2 (uk) 2019-03-25

Family

ID=47715521

Family Applications (1)

Application Number Title Priority Date Filing Date
UAA201401344A UA118833C2 (uk) 2011-08-17 2012-08-13 Одиничний варіабельний домен імуноглобуліну, який зв'язується з tnfr1

Country Status (25)

Country Link
US (3) US10808040B2 (enExample)
EP (3) EP2987806A3 (enExample)
JP (3) JP6297976B2 (enExample)
KR (2) KR102143506B1 (enExample)
CN (2) CN103917557B (enExample)
AR (1) AR087521A1 (enExample)
AU (3) AU2012296961B2 (enExample)
BR (1) BR112014003679B1 (enExample)
CA (1) CA2845029A1 (enExample)
CO (1) CO7020851A2 (enExample)
DO (1) DOP2014000029A (enExample)
EA (1) EA027160B1 (enExample)
ES (1) ES2813432T3 (enExample)
HK (1) HK1214281A1 (enExample)
IL (1) IL230918A0 (enExample)
MA (1) MA35428B1 (enExample)
MX (1) MX2014001883A (enExample)
MY (1) MY167125A (enExample)
PE (1) PE20141522A1 (enExample)
PH (1) PH12014500380A1 (enExample)
SG (2) SG2014010482A (enExample)
TW (1) TW201321405A (enExample)
UA (1) UA118833C2 (enExample)
UY (1) UY34254A (enExample)
WO (1) WO2013024059A2 (enExample)

Families Citing this family (99)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
ES2691717T3 (es) 2009-10-30 2018-11-28 Novartis Ag Bibliotecas universales del dominio de unión del lado inferior de tipo iii de la fibronectina de tipo III
EP2621953B1 (en) 2010-09-30 2017-04-05 Ablynx N.V. Biological materials related to c-met
US11644471B2 (en) 2010-09-30 2023-05-09 Ablynx N.V. Techniques for predicting, detecting and reducing aspecific protein interference in assays involving immunoglobulin single variable domains
SG10201805064SA (en) 2011-06-23 2018-07-30 Ablynx Nv Techniques for predicting, detecting and reducing aspecific protein interference in assays involving immunoglobulin single variable domains
EP2723771B1 (en) 2011-06-23 2019-09-11 Ablynx NV Serum albumin binding proteins
RS55775B2 (sr) * 2011-06-23 2022-10-31 Ablynx Nv Tehnike za predviđanje, otkrivanje i smanjenje nespecifične proteinske interferencije u testovima koji uključuju pojedinačne varijabilne domene imunoglobulina
EP4350345A3 (en) * 2011-06-23 2024-07-24 Ablynx N.V. Techniques for predicting, detecting and reducing aspecific protein interference in assays involving immunoglobin single variable domains
PE20141522A1 (es) * 2011-08-17 2014-11-17 Glaxo Group Ltd Proteinas y peptidos modificados
US9346884B2 (en) 2011-09-30 2016-05-24 Ablynx N.V. Biological materials related to c-Met
US9328174B2 (en) 2012-05-09 2016-05-03 Novartis Ag Chemokine receptor binding polypeptides
WO2014043509A2 (en) * 2012-09-13 2014-03-20 Novartis Ag Antigen binding molecule with terminal modifications
WO2014111550A1 (en) * 2013-01-17 2014-07-24 Glaxosmithkline Intellectual Property Development Limited Modified anti-serum albumin binding proteins
WO2015104322A1 (en) * 2014-01-09 2015-07-16 Glaxosmithkline Intellectual Property Development Limited Treatment of inflammatory diseases with non-competitive tnfr1 antagonists
EP4707303A2 (en) * 2014-05-16 2026-03-11 Ablynx NV Improved immunoglobulin variable domains
IL318433A (en) 2014-05-16 2025-03-01 Ablynx Nv Improved immunoglobulin variable complexes
US11009511B2 (en) 2014-05-16 2021-05-18 Ablynx N.V. Methods for detecting and/or measuring anti-drug antibodies, in particular treatment-emergent anti-drug antibodies
NL2013007B1 (en) 2014-06-16 2016-07-05 Ablynx Nv Methods of treating TTP with immunoglobulin single variable domains and uses thereof.
MX375669B (es) * 2014-09-26 2025-03-06 Macrogenics Inc Diacuerpos monovalentes biespecificos que son capaces de unir cd19 y cd3, y usos de los mismos.
JP7001474B2 (ja) 2015-01-21 2022-01-19 インヒブルクス，インコーポレイティド 非免疫原性単一ドメイン抗体
EP3271391A1 (en) * 2015-03-20 2018-01-24 Ablynx N.V. Glycosylated immunoglobulin single variable domains
SG11201706840WA (en) 2015-03-31 2017-09-28 Vhsquared Ltd Peptide construct having a protease-cleavable linker
CA3255406A1 (en) 2015-03-31 2025-07-03 Sorriso Pharmaceuticals, Inc. Tnf-alpha binding polypeptides
WO2016156468A1 (en) 2015-03-31 2016-10-06 Vhsquared Limited Polypeptides
CA2991634C (en) * 2015-07-16 2026-03-17 Inhibrx Biosciences, Inc. Multivalent and multispecific dr5-binding fusion proteins
US12048753B2 (en) 2015-10-01 2024-07-30 Whitehead Institute For Biomedical Research Labeling of antibodies
CN108350069B (zh) 2015-10-30 2021-11-12 埃博灵克斯股份有限公司 针对il-23的多肽
HRP20220064T1 (hr) * 2015-10-30 2022-04-15 F. Hoffmann - La Roche Ag Zglobno modificirani fragmenti protutijela i postupci za pripravu
NO2768984T3 (enExample) * 2015-11-12 2018-06-09
EP3374395A1 (en) 2015-11-12 2018-09-19 Ablynx NV Improved p2x7 receptor binders and polypeptides comprising the same
LT3374392T (lt) 2015-11-13 2022-01-25 Ablynx Nv Patobulinti serumo albuminą surišantys imunoglobulino kintami domenai
CA3003777A1 (en) * 2015-11-18 2017-05-26 Merck Sharp & Dohme Corp. Pd1/ctla4 binders
AU2016355569B2 (en) 2015-11-18 2020-01-02 Merck Sharp & Dohme Llc CTLA4 binders
AU2016357460B2 (en) * 2015-11-18 2023-07-27 Ablynx Nv Improved serum albumin binders
IL300122A (en) 2015-11-18 2023-03-01 Merck Sharp ַ& Dohme Llc Substances that bind to PD1 and/or LAG3
KR20180080337A (ko) 2015-11-27 2018-07-11 아블린쓰 엔.브이. Ｃｄ40ｌ을 억제하는 폴리펩티드
UA122079C2 (uk) 2015-12-04 2020-09-10 Бьорінгер Інгельхайм Інтернаціональ Гмбх Поліпептид, що специфічно зв'язується з lrp5 і lrp6
GB201522539D0 (en) 2015-12-21 2016-02-03 Hexcel Composites Ltd Improvements in or relating to electrically conducting materials
AU2017281421B2 (en) * 2016-06-23 2024-07-25 Ablynx N.V. Improved pharmacokinetic assays for immunoglobulin single variable domains
EP3519438A1 (en) 2016-09-30 2019-08-07 VHsquared Limited Compositions
RU2022101604A (ru) 2016-12-07 2022-03-29 Аблинкс Нв Улучшенные отдельные вариабельные домены иммуноглобулина, связывающиеся с сывороточным альбумином
JP7219220B2 (ja) 2017-01-17 2023-02-07 アブリンクス エン．ヴェー． 改善された血清アルブミン結合剤
IL267897B2 (en) 2017-01-17 2025-02-01 Ablynx Nv Improved serum albumin binders
US12480957B2 (en) 2017-03-31 2025-11-25 Ablynx N.V. Method of screening for anti-drug antibodies against immunoglobulin single variable domain-based drugs
EP3630816B1 (en) 2017-05-31 2024-03-20 Boehringer Ingelheim International GmbH Polypeptides antagonizing wnt signaling in tumor cells
CN111356700A (zh) 2017-09-08 2020-06-30 马弗里克治疗公司 受约束的条件性活化的结合蛋白
US11919949B2 (en) 2017-09-27 2024-03-05 Elasmogen Ltd Specific binding molecules
EP3749696A1 (en) * 2018-02-06 2020-12-16 Ablynx N.V. Methods of treating initial episode of ttp with immunoglobulin single variable domains
EP3569618A1 (en) 2018-05-19 2019-11-20 Boehringer Ingelheim International GmbH Antagonizing cd73 antibody
TWI848953B (zh) 2018-06-09 2024-07-21 德商百靈佳殷格翰國際股份有限公司 針對癌症治療之多特異性結合蛋白
AR115730A1 (es) * 2018-07-10 2021-02-17 Regeneron Pharma Modificación de moléculas de unión para minimizar interacciones pre-existentes
CN109096394B (zh) * 2018-09-21 2021-11-05 成都阿帕克生物科技有限公司 一种抗葡萄球菌蛋白a的b亚单位的纳米抗体及核酸分子和应用
FR3088640A1 (fr) 2018-10-14 2020-05-22 Smart Diagnostix Pharma Nouveau polypeptide se liant specifiquement a la proteine p16
US20230053449A1 (en) 2018-10-31 2023-02-23 Novartis Ag Dc-sign antibody drug conjugates
GB201818460D0 (en) * 2018-11-13 2018-12-26 Crescendo Biologics Ltd Single domain antibodies that bind human serum albumin
EP4592313A3 (en) 2019-03-05 2025-11-19 Takeda Pharmaceutical Company Limited Constrained conditionally activated binding proteins
CA3144567A1 (en) 2019-06-21 2020-12-24 Scott Crowe Polypeptides
KR20220063148A (ko) 2019-06-21 2022-05-17 소리소 파마슈티컬스 인크. 조성물
US12559552B2 (en) 2019-06-21 2026-02-24 Sorriso Pharmaceuticals, Inc. IL-23 and TNF-alpha binding bi-specific heavy chain polypeptides
TWI878355B (zh) 2019-10-02 2025-04-01 德商百靈佳殷格翰國際股份有限公司 用於癌症治療之多重專一性結合蛋白
GB201914468D0 (en) 2019-10-07 2019-11-20 Crescendo Biologics Ltd Binding Molecules
IL293725A (en) 2019-12-11 2022-08-01 Cullinan Oncology Inc Anti-cd19 antibodies and multispecific binding proteins
IL293780A (en) * 2019-12-11 2022-08-01 Cullinan Man Inc Anti-serum albumin antibodies
AR121706A1 (es) * 2020-04-01 2022-06-29 Hoffmann La Roche Moléculas de unión a antígeno biespecíficas dirigidas a ox40 y fap
EP4196503A2 (en) 2020-08-17 2023-06-21 Takeda Pharmaceutical Company Limited Constrained conditionally activated binding proteins
CN117903303A (zh) * 2020-08-20 2024-04-19 南京融捷康生物科技有限公司 Il-5的结合分子及其应用
CA3193273A1 (en) * 2020-08-27 2022-03-03 Enosi Therapeutics Corporation Methods and compositions to treat autoimmune diseases and cancer
US20230312715A1 (en) 2020-09-04 2023-10-05 Takeda Pharmaceutical Company Limited Constrained conditionally activated binding protein constructs with human serum albumin domains
WO2022081460A1 (en) * 2020-10-12 2022-04-21 Janssen Biotech, Inc. Biosynthetic materials and methods for multidirectional biotransportation
CN113307870B (zh) * 2020-10-30 2022-12-23 上海洛启生物医药技术有限公司 抗il5纳米抗体及其应用
CN116964090A (zh) 2020-12-14 2023-10-27 武田药品工业有限公司 条件性双特异性结合蛋白
CN112341543B (zh) * 2021-01-11 2021-04-23 广东赛尔生物科技有限公司 包含间充质干细胞外泌体的药物组合物在治疗疾病中的应用
BR112023020437A2 (pt) 2021-04-06 2024-04-30 Takeda Pharmaceuticals Co Métodos terapêuticos usando proteínas de ligação ativadas condicionalmente restritas
US20250026842A1 (en) * 2021-11-29 2025-01-23 Jiangsu Hengrui Pharmaceuticals Co., Ltd. Modified protein or polypeptide
EP4448783A1 (en) 2021-12-13 2024-10-23 Heraeus Medical GmbH Tests and methods for detecting bacterial infection
AU2023212292A1 (en) * 2022-01-27 2024-09-12 Janssen Biotech, Inc. Enhanced protein compositions
AR128593A1 (es) 2022-02-23 2024-05-22 Takeda Pharmaceuticals Co Proteínas de unión condicionalmente biespecíficas
US20240132624A1 (en) 2022-07-27 2024-04-25 Ablynx N.V. Polypeptides binding to a specific epitope of the neonatal fc receptor
EP4357778A1 (en) 2022-10-20 2024-04-24 Heraeus Medical GmbH Treatment of microbial infections diagnosed using the biomarker d-lactate
CN115819599B (zh) * 2022-11-29 2024-01-16 江苏耀海生物制药有限公司 一种利用重组大肠杆菌分泌表达纳米抗体Cablivi的方法
JP2026503077A (ja) 2023-01-09 2026-01-27 オデッセイ セラピューティクス，インコーポレイテッド 抗ｔｎｆｒ２抗原結合タンパク質及びその使用
TW202448926A (zh) 2023-02-17 2024-12-16 比利時商艾伯霖克斯公司 結合新生兒fc受體之多肽
TW202444757A (zh) 2023-03-14 2024-11-16 美商奧迪希治療公司 抗cd25抗原結合蛋白及其用途
CN121666535A (zh) * 2023-04-20 2026-03-13 赞特里亚公司 用于检测针对抗TNFα抗体的抗药物抗体(ADA)的方法
EP4713364A1 (en) * 2023-05-17 2026-03-25 Odyssey Therapeutics, Inc. Modified single-domain antibodies
KR20260032566A (ko) 2023-06-29 2026-03-09 오디세이 테라퓨틱스, 인코포레이티드 항-trailr2 항원-결합 단백질 및 그의 용도
WO2025008537A1 (en) 2023-07-05 2025-01-09 Ablynx Nv Improved fcrn antagonists for treatment of igg-related diseases and disorders
WO2025049948A1 (en) 2023-08-30 2025-03-06 Xilio Development, Inc. Masked il-2 cytokines and methods of use thereof
AU2024330564A1 (en) 2023-08-30 2026-04-02 Xilio Development, Inc. Vhh masked cytokines and methods of use thereof
TW202532432A (zh) 2023-09-22 2025-08-16 比利時商艾伯霖克斯公司 二及多價白蛋白結合劑
TW202530265A (zh) 2023-10-13 2025-08-01 美商奧迪希治療公司 抗cdh17抗原結合蛋白及其用途
CN119173537A (zh) * 2024-01-03 2024-12-20 苏州智核生物医药科技有限公司 经修饰的免疫球蛋白单一可变结构域
US20250250314A1 (en) 2024-01-10 2025-08-07 Xilio Development, Inc. Masked il-2 cytokines and methods of use thereof
WO2025167664A1 (zh) * 2024-02-07 2025-08-14 原启生物科技(上海)有限责任公司 Ror1抗原结合蛋白及其用途
CN120025456B (zh) * 2024-03-13 2025-11-07 寻济生物科技（北京）有限公司 一种抗vegfa融合构建体及其制备方法和应用
WO2025217240A1 (en) 2024-04-10 2025-10-16 Odyssey Therapeutics, Inc. Anti-tnfr2 antigen-binding proteins and uses thereof
WO2025255435A2 (en) 2024-06-07 2025-12-11 Odyssey Therapeutics, Inc. Antigen-binding proteins against serum albumin and uses thereof
WO2025255558A2 (en) 2024-06-07 2025-12-11 Odyssey Therapeutics, Inc. Anti-thymic stromal lymphopoietin (tslp) antigen-binding proteins and uses thereof
WO2026006809A1 (en) 2024-06-27 2026-01-02 Odyssey Therapeutics, Inc. Multispecific molecules binding tnfr2 and cd25 and uses thereof
WO2026006708A2 (en) 2024-06-27 2026-01-02 Odyssey Therapeutics, Inc. Anti-cd25 antigen-binding proteins and uses thereof

Family Cites Families (41)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
ATE158021T1 (de) 1990-08-29 1997-09-15 Genpharm Int Produktion und nützung nicht-menschliche transgentiere zur produktion heterologe antikörper
DK1621554T4 (da) 1992-08-21 2012-12-17 Univ Bruxelles Immunoglobuliner blottet for lette kæder
FR2708622B1 (fr) 1993-08-02 1997-04-18 Raymond Hamers Vecteur recombinant contenant une séquence d'un gène de lipoprotéine de structure pour l'expression de séquences de nucléotides.
IL127127A0 (en) * 1998-11-18 1999-09-22 Peptor Ltd Small functional units of antibody heavy chain variable regions
US20050271663A1 (en) 2001-06-28 2005-12-08 Domantis Limited Compositions and methods for treating inflammatory disorders
US20060073141A1 (en) * 2001-06-28 2006-04-06 Domantis Limited Compositions and methods for treating inflammatory disorders
AU2003210060B2 (en) 2002-03-22 2010-02-25 Aprogen, Inc. Humanized antibody and process for preparing same
AU2003244817B2 (en) 2002-06-28 2010-08-26 Domantis Limited Antigen-binding immunoglobulin single variable domains and dual-specific constructs
US7563443B2 (en) * 2004-09-17 2009-07-21 Domantis Limited Monovalent anti-CD40L antibody polypeptides and compositions thereof
GB0521621D0 (en) 2005-10-24 2005-11-30 Domantis Ltd Tumor necrosis factor receptor 1 antagonists for treating respiratory diseases
ES2694247T3 (es) * 2005-05-20 2018-12-19 Ablynx N.V. NanobodiesTM mejorados para el tratamiento de trastornos mediados por agregación
DE102005023617A1 (de) * 2005-05-21 2006-11-23 Aspre Ag Verfahren zum Mischen von Farben in einem Display
JP2007008925A (ja) 2005-05-31 2007-01-18 Canon Inc 標的物質捕捉分子
WO2006129843A2 (en) * 2005-05-31 2006-12-07 Canon Kabushiki Kaisha Bispecific capturing molecule
US20100323905A1 (en) * 2005-09-23 2010-12-23 Academisch Ziekenhuis Leiden Vhh for the Diagnosis, Prevention and Treatment of Diseases Associated with Protein Aggregates
EA200801166A1 (ru) * 2005-12-01 2008-12-30 Домантис Лимитед Форматы конкурентного доменного антитела, которые связываются с рецептором интерлейкина 1 первого типа
JP2009519011A (ja) * 2005-12-01 2009-05-14 ドマンティス リミテッド インターロイキン１受容体１型に結合する非競合ドメイン抗体フォーマット
US20100047171A1 (en) 2006-01-24 2010-02-25 Roland Beckmann Fusion Proteins That Contain Natural Junctions
WO2008020079A1 (en) 2006-08-18 2008-02-21 Ablynx N.V. Amino acid sequences directed against il-6r and polypeptides comprising the same for the treatment of deseases and disorders associated with il-6-mediated signalling
EP2121018A2 (en) * 2006-12-13 2009-11-25 Schering Corporation Treating cancer with anti-igf1r antibody 19d12=sch 717454
EP2158318A2 (en) 2007-05-14 2010-03-03 Biogen Idec MA, Inc. Single-chain fc (scfc) regions, binding polypeptides comprising same, and methods related thereto
CA2688433A1 (en) * 2007-06-06 2008-12-11 Domantis Limited Methods for selecting protease resistant polypeptides
GB0724331D0 (en) 2007-12-13 2008-01-23 Domantis Ltd Compositions for pulmonary delivery
JP2010528647A (ja) 2007-06-06 2010-08-26 ドマンティス リミテッド ポリペプチド、抗体可変ドメインおよびアンタゴニスト
EP2650311A3 (en) * 2007-11-27 2014-06-04 Ablynx N.V. Amino acid sequences directed against heterodimeric cytokines and/or their receptors and polypeptides comprising the same
US20090148905A1 (en) 2007-11-30 2009-06-11 Claire Ashman Antigen-binding constructs
EP2220115A2 (en) 2007-12-13 2010-08-25 Glaxo Group Limited Polypeptides, antibody variable domains & antagonists
EP2252303A2 (en) 2008-03-21 2010-11-24 Ablynx NV Von willebrand factor specific binders and methods of use therefor
US8020937B2 (en) * 2008-07-31 2011-09-20 Lear Corporation Layered technology for energy management of vehicle seating
JP2011530297A (ja) 2008-08-14 2011-12-22 セファロン・オーストラリア・ピーティーワイ・リミテッド バリアントドメイン抗体
CA2738243C (en) 2008-10-29 2020-09-29 Wyeth Llc Formulations of single domain antigen binding molecules
US10005830B2 (en) 2009-03-05 2018-06-26 Ablynx N.V. Antigen binding dimer-complexes, methods of making/avoiding and uses thereof
NZ595461A (en) * 2009-04-10 2013-01-25 Ablynx Nv Improved amino acid sequences directed against il-6r and polypeptides comprising the same for the treatment of il-6r related diseases and disorders
WO2011003622A1 (en) * 2009-07-10 2011-01-13 Ablynx N.V. Method for the production of variable domains
GB201005063D0 (en) 2010-03-25 2010-05-12 Ucb Pharma Sa Biological products
CA2784498A1 (en) * 2009-12-18 2011-06-23 Sanofi Novel antagonist antibodies and their fab fragments against gpvi and uses thereof
EP2621953B1 (en) * 2010-09-30 2017-04-05 Ablynx N.V. Biological materials related to c-met
RS55775B2 (sr) * 2011-06-23 2022-10-31 Ablynx Nv Tehnike za predviđanje, otkrivanje i smanjenje nespecifične proteinske interferencije u testovima koji uključuju pojedinačne varijabilne domene imunoglobulina
SG10201805064SA (en) * 2011-06-23 2018-07-30 Ablynx Nv Techniques for predicting, detecting and reducing aspecific protein interference in assays involving immunoglobulin single variable domains
PE20141522A1 (es) * 2011-08-17 2014-11-17 Glaxo Group Ltd Proteinas y peptidos modificados
WO2014111550A1 (en) 2013-01-17 2014-07-24 Glaxosmithkline Intellectual Property Development Limited Modified anti-serum albumin binding proteins

Also Published As

Publication number Publication date
CO7020851A2 (es) 2014-08-11
TW201321405A (zh) 2013-06-01
KR102143506B1 (ko) 2020-08-12
EP3339322A2 (en) 2018-06-27
WO2013024059A3 (en) 2014-05-30
JP2018117623A (ja) 2018-08-02
DOP2014000029A (es) 2014-10-31
SG10201605891TA (en) 2016-09-29
KR102162413B1 (ko) 2020-10-07
KR20190113996A (ko) 2019-10-08
AU2016277685A1 (en) 2017-01-19
CA2845029A1 (en) 2013-02-21
CN108178800B (zh) 2022-06-17
US10808040B2 (en) 2020-10-20
US20210017293A1 (en) 2021-01-21
EA027160B1 (ru) 2017-06-30
JP6297976B2 (ja) 2018-03-20
PE20141522A1 (es) 2014-11-17
UY34254A (es) 2013-04-05
IL230918A0 (en) 2014-03-31
JP2020054374A (ja) 2020-04-09
CN103917557B (zh) 2018-03-20
NZ621203A (en) 2016-03-31
EP2744822B1 (en) 2020-06-24
EA201490262A1 (ru) 2014-09-30
HK1214281A1 (en) 2016-07-22
AR087521A1 (es) 2014-03-26
BR112014003679A2 (pt) 2017-03-07
WO2013024059A2 (en) 2013-02-21
BR112014003679B1 (pt) 2022-08-30
EP2987806A2 (en) 2016-02-24
ES2813432T3 (es) 2021-03-23
AU2012296961B2 (en) 2017-02-16
CN108178800A (zh) 2018-06-19
SG2014010482A (en) 2014-04-28
MA35428B1 (fr) 2014-09-01
PH12014500380A1 (en) 2022-05-02
WO2013024059A9 (en) 2014-04-03
KR20140054262A (ko) 2014-05-08
AU2016277685B2 (en) 2019-03-28
AU2019201505A1 (en) 2019-03-28
EP2744822A2 (en) 2014-06-25
CN103917557A (zh) 2014-07-09
MY167125A (en) 2018-08-13
MX2014001883A (es) 2014-05-27
JP6979446B2 (ja) 2021-12-15
EP3339322A3 (en) 2018-10-31
EP2987806A3 (en) 2016-07-13
US20250136721A1 (en) 2025-05-01
US20140227259A1 (en) 2014-08-14
JP2014525752A (ja) 2014-10-02
AU2012296961A1 (en) 2014-03-13

Similar Documents

Publication Publication Date Title
UA118833C2 (uk) Одиничний варіабельний домен імуноглобуліну, який зв'язується з tnfr1
US20200277365A1 (en) Antagonist antibodies against gdf-8 and uses therefor
EP3119432B1 (en) Antibodies against immunogenic glycopeptides, composition comprising the same and use thereof
JP6797111B2 (ja) イヌｐｄ−ｌ１と結合するｐｄ−ｌ１抗体
TWI613216B (zh) 經生物工程之抗－ＴＧＦ－β抗體及抗原結合片段
EP2407486B1 (en) Antagonist antibodies against GDF-8 and uses in treatment of ALS and other GDF-8-associated disorders
JP5564049B2 (ja) 抗ｃｄ１４７抗体、方法及び使用
US9926375B2 (en) Anti-endoglin antibodies and uses thereof
HUE033960T2 (en) Monoclonal Antibodies to ANGPTL3
SG177189A1 (en) Human antibodies to human delta like ligand 4
JP2017536354A (ja) 抗プロ／潜在型−ミオスタチン抗体およびその使用
CN113173993A (zh) 拮抗性抗犬pd-1抗体
UA125757C2 (uk) Антитіло до par2 і його застосування
JP2021506748A (ja) 抗ｐｄ‐ｌ１抗体とｉｌ‐７との融合
AU5007901A (en) Antibodies against SEMP1, methods for their production and uses thereof
US20260035440A1 (en) Anti-etec adhesin protein antibodies and methods of use
US12509512B2 (en) Semaphorin 3A antibodies and uses thereof
CN116437953A (zh) 治疗血管渗漏的方法和组合物
TW202146458A (zh) 一種抗PD-L1/TGF-β融合蛋白
WO2021197340A1 (zh) 用于治疗冠状病毒的抗体、融合蛋白及其应用
JP7849919B2 (ja) ヒトｄｒ３に特異的に結合する抗体及びその用途
KR20230175116A (ko) 인간 dr3에 특이적으로 결합하는 항체 및 이의 용도
WO2022226079A1 (en) Neutralizing antibodies against sars-cov-2
TW202506196A (zh) 含有糖皮質激素的抗體藥物偶聯物的藥物組合物
HK1165432B (en) Antagonist antibodies against gdf-8 and uses in treatment of als and other gdf-8-associated disorders